FDA OKs Ampyra To Improve Walking In Adults With Multiple Sclerosis
January 22 2010 - 4:28PM
Dow Jones News
The U.S. Food and Drug Administration Friday approved a new drug
from Acorda Therapeutics Inc. (ACOR) to improve walking in patients
with multiple sclerosis.
The FDA said the drug, Ampyra, is the first drug approved to
improve walking in MS patients.
The agency said clinical trials showed patients treated with
Ampyra had faster walking speeds than those treated with a placebo
or fake pill.
Multiple sclerosis is a progressive disease that involves damage
to nerves controlling muscles and vision; it affects about 400,000
Americans. The condition causes the body's immune system to eat
away at the protective covering of the nerves, or myelin, which
disrupts the electrical signals between the brain and the rest of
the body.
Ampyra is designed to help the body's electric signals pass
through by blocking potassium ions that leak from the damaged
nerves.
The FDA said the product will be manufactured under licenses
from Elan Corp. PLC (ELN) of Dublin, Ireland, and distributed by
Acorda, Hawthorne, N.Y. Acord shares recently rose 9% to $28.
-By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294;
jennifer.corbett@dowjones.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Apr 2023 to Apr 2024